Latest Conference Coverage

Tanuja Chitnis, MD: Nfl Levels In Long-Term MS Outcomes

The professor of neurology at Harvard Medical School spoke about the long-term correlations between neurofilament light chain and MS outcomes.

Antje Bischof, MD: Accelerated Cord Atrophy Precedes Conversion to SPMS in RRMS

The Postdoctoral Scholar at the University of California San Francisco spoke about a longitudinal study that evaluated the utility of spinal cord atrophy measured from brain scans as a surrogate marker for impending conversion to secondary progressive MS.

Marisa McGinley, DO: Using Quantitative MRI in Multiple Sclerosis

The staff neurologist at the Mellen Center shared the findings from a poster the group presented from the cohort of patients in which they evaluated quantitative MRI.

Daniel Ontaneda, MD, PhD: Real-World Observations With Ocrelizumab

The staff neurologist at Cleveland Clinic's Mellen Center spoke about the real-world observational study of the primary-progressive MS treatment.

Marisa McGinley, DO: Improving Comprehensive MS Care

The staff neurologist at Cleveland Clinic's Mellen Center spoke about re-examining patient-reported outcomes to better understand the quality of life of patients and how it can affect clinical care.

Dina Katabi, PhD: Biosensors for Measuring Disease Activity in MS and Other Neurological Disorders

The Andrew & Erna Viterbi Professor of Electrical Engineering and Computer Science at MIT spoke about a new way of continuous monitoring for patients with MS and neurodegenerative disorders, discovering changes in quality of life and new biomarkers.

Tal Arbel, PhD: Approaching Multiple Sclerosis with Machine Learning

The director of the probabilistic vision group and medical imaging lab at McGill University spoke about how these learning methods can be used to predict future lesion activity and disability progression in MS.

Assessing the Value MS Centers Provide to Patients and Institutions

The chief of the Multiple Sclerosis Division at the Perelman School of Medicine discussed the importance of institutions recognizing the value a comprehensive MS clinic can provide not only to the patients but the institution itself.

Fred Lublin, MD: Current Challenges in MS

The director of the Corinne Goldsmith Dickinson Center for MS at Mount Sinai School of Medicine spoke about the major issues in MS right now: being able to individually prognosticate, moving toward developing better therapies for a progressive disease, and repairing the damage to the nervous system.

Daniel Ontaneda, MD, PhD: Diagnosing MS With the Central Vein Sign

The staff neurologist at the Mellen Center for MS at Cleveland Clinic spoke about the potential for the central vein sign to help address issues of misdiagnosis in multiple sclerosis

Can Cladribine Get FDA Approval in Multiple Sclerosis Now With Long-Term Data?

The vice president of US Medical Affairs in Neurology and Immunology at EMD Serono spoke to the next steps for the oral agent and its potential to get approved by the FDA in 2019.

Mark Freedman, MD: Long-Term Efficacy and Safety Studies in MS

The director of the multiple sclerosis research unit at Ottawa Hospital spoke about the importance of long-term efficacy studies.

Marisa McGinley, DO: Taking a Comprehensive Approach to MS

The staff neurologist at Cleveland Clinic's Mellen Center spoke about the importance of a comprehensive approach to managing patients with multiple sclerosis.

More Multiple Sclerosis Centers Are Needed To Overcome Challenges

The chief of the Multiple Sclerosis Division at the University of Pennsylvania’s Perelman School of Medicine spoke about the need for more team-based care for patients with MS.

Collecting Age-Matched Long-Term Data in MS With Cladribine

The vice president of US Medical Affairs in Neurology & Immunology at EMD Serono discussed the importance of having long-term and age-matched data on the use of the investigational oral agent in MS.

Tanuja Chitnis, MD: Diagnosing Pediatric MS

The professor of neurology at Harvard Medical School shared her methods for diagnosing pediatric MS and about the importance of managing the disease in a larger sense.

Predicting Multiple Sclerosis Progression, Lesion Activity With Machine and Deep Learning

The director of the probabilistic vision group and medical imaging lab at McGill University spoke about machine learning’s potential to help physicians predict MS disease progression, treatment effectiveness, and more.

Howard Weiner, MD: Entering a New Era in MS

The director of the Partners Multiple Sclerosis Center at Brigham and Women's Hospital spoke about the future of multiple sclerosis.

Cervical Cord Atrophy May Be Indicative of Progression to Secondary Progressive MS

The spinal cord area has shown a strong link to MS disability and can help discriminate progressive and relapsing-remitting disease subtypes, which in turn could help inform individualized treatment plans.

Joseph Berger, MD: The Need for More MS Specialists

The professor of neurology spoke about the challenges faced by MS specialists as their numbers dwindle and the number of patients surpasses 1 million in the United States.

Daniel Ontaneda, MD, PhD: The Problem of Misdiagnosis in Multiple Sclerosis

The staff neurologist at the Mellen Center for MS at Cleveland Clinic discussed this challenge with misdiagnosis and how it impacts the clinicians who are treating these patients.

Cladribine Associated With Long-Term Sustained NEDA-3 Status in MS

A pair of poster presentations regarding the use of cladribine in multiple sclerosis have shown that No Evidence of Disease Activity-3 status can be sustained up to 4 years, without any new safety signals appearing.

Are Neurologists Adhering to Multiple Sclerosis Treatment Guidelines?

Data have suggested that neurologists treating MS have clearly and persistently deviated from the readily available evidence regarding DMT use, all while costs continue to rise and payers intensify efforts to control them.

Is DMT Use Safe For Elderly Patients with Multiple Sclerosis?

A late-breaking poster has suggested that the use of disease-modifying therapy is safe in patients with MS over the age of 65, as well as that disability burden and relapse rates may be lower than believed.

Ruth Ann Marrie, MD, PhD: Role of Comorbidities in MS

The professor of medicine and community health sciences at the University of Manitoba spoke about the effects of comorbidity on diagnosis, outcomes, and treatment in multiple sclerosis.

Tanuja Chitnis, MD: Differentiating Pediatric MS From Other Demyelinating Disorders

The professor of neurology at Harvard Medical School provided some insight into her experience with treating pediatric patients with MS.

Zhibin Chen, PhD: Treatment Gap in Patients with Newly Diagnosed Epilepsy

Despite accessibility to antiepileptic drugs in high-income settings, more than one-third of patients with newly diagnosed epilepsy were not treated or had delayed treatment.

Joseph Sullivan, MD: Efficacy of ZX008 in Dravet Syndrome

The director of the Pediatric Epilepsy Center at UCSF Benioff Children’s Hospital discussed the efficacy profile of ZX008, for which Zogenix recently submitted a new drug application to the FDA for the treatment of Dravet syndrome.

Obtaining Routine EEG While Managing Epilepsy

The neurologist and epileptologist at the Mayo Clinic in Jacksonville discussed when to best perform routine EEG in patients with epilepsy.

Seizure Worsening in Pregnancy, Postpartum is Influenced by Epilepsy Type

The attending neurologist at Brigham and Women's Hospital spoke about data from an analysis that concluded that women with frontal lobe epilepsy are more likely to experience a worsening of their seizure frequency during pregnancy.